Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson’s Disease Models
暂无分享,去创建一个
J. Hong | D. Son | S. Han | In Jun Yeo | Haksup Lee | J. Yun | Seongsill Jeon | Hyeon Joo Ham | J. Lim | Sung Sik Yoo | Sung-Su Jang | Seung-Jin Shin | I. Yeo
[1] D. Devos,et al. Protein network exploration prioritizes targets for modulating neuroinflammation in Parkinson's disease. , 2021, International immunopharmacology.
[2] Guy C. Brown,et al. Microglial phagocytosis of neurons in neurodegeneration, and its regulation , 2021, Journal of neurochemistry.
[3] P. Illés,et al. Astrocytic and Oligodendrocytic P2X7 Receptors Determine Neuronal Functions in the CNS , 2021, Frontiers in Molecular Neuroscience.
[4] C. Hölscher,et al. Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model. , 2021, Journal of Parkinson's disease.
[5] C. Hölscher,et al. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model , 2021, Neural regeneration research.
[6] A. A. Del Bel Cury,et al. Modulatory effect of botulinum toxin type A on the microglial P2X7/CatS/FKN activated-pathway in antigen-induced arthritis of the temporomandibular joint of rats. , 2020, Toxicon : official journal of the International Society on Toxinology.
[7] A. Piotrowska,et al. Botulinum Toxin Type A—A Modulator of Spinal Neuron–Glia Interactions under Neuropathic Pain Conditions , 2018, Toxins.
[8] A. Piotrowska,et al. Comparison of the Expression Changes after Botulinum Toxin Type A and Minocycline Administration in Lipopolysaccharide-Stimulated Rat Microglial and Astroglial Cultures , 2017, Front. Cell. Infect. Microbiol..
[9] Chenglei Fan,et al. Intra‐articular injection of Botulinum toxin A reduces neurogenic inflammation in CFA‐induced arthritic rat model , 2017, Toxicon : official journal of the International Society on Toxinology.
[10] J. Hong,et al. Parkin deficiency exacerbate ethanol-induced dopaminergic neurodegeneration by P38 pathway dependent inhibition of autophagy and mitochondrial function , 2016, Redox biology.
[11] N. Jetté,et al. The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.
[12] A. Lang,et al. Pharmacological treatment of Parkinson disease: a review. , 2014, JAMA.
[13] K. Juenemann,et al. Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice , 2014, Therapeutic advances in urology.
[14] R. Benecke,et al. Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease , 2013, Journal of neuroscience research.
[15] J. Hong,et al. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration , 2013, Neurobiology of Disease.
[16] C. Ríos,et al. Medical Management of Parkinson’s Disease: Focus on Neuroprotection , 2011, Current neuropharmacology.
[17] Jun B. Ding,et al. Cholinergic modulation of synaptic integration and dendritic excitability in the striatum , 2011, Current Opinion in Neurobiology.
[18] G. Bing,et al. Lipopolysaccharide Animal Models for Parkinson's Disease , 2011, Parkinson's disease.
[19] R. Benecke,et al. Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease , 2011, Neurobiology of Disease.
[20] Xiuzhen Yan,et al. Neuritogenic Actions of Botulinum Neurotoxin A on Cultured Motor Neurons , 2009, Journal of Pharmacology and Experimental Therapeutics.
[21] S. Resim,et al. Botulinum toxin-A to improve urethral wound healing: an experimental study in a rat model. , 2009, Urology.
[22] C. Ferrari,et al. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease , 2008, Brain : a journal of neurology.
[23] M. Stubblefield,et al. The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report. , 2008, Archives of physical medicine and rehabilitation.
[24] Charles J. Wilson,et al. RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion , 2006, Nature Neuroscience.
[25] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.
[26] A. Sampson,et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models , 2006, Nature Neuroscience.
[27] J. Jankovic,et al. Botulinum toxin in clinical practice , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[28] C. Marsden. The mysterious motor function of the basal ganglia , 1982, Neurology.
[29] Zoë Dodd. TREATMENT , 1922, Cesare Zavattini Selected Writings.
[30] R. Benecke,et al. Intracerebrally applied botulinum neurotoxin in experimental neuroscience. , 2013, Current pharmaceutical biotechnology.
[31] R. Compans,et al. Botulinum Neurotoxins , 2013, Current Topics in Microbiology and Immunology.
[32] K. Yokote. [Pharmacological treatment]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.
[33] P. Riederer,et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. , 1994, Neuroscience letters.
[34] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .